Trial Profile

A Phase I/II Study of PR-001 in Patients with Neuronopathic Gaucher's-Disease-Type-III

Status: Planning

Phase of Trial: Phase I/II

Latest Information Update: 28 Nov 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs PR 001 (Primary)
Indications Gaucher's disease type III
Focus Therapeutic Use
Acronyms PROGRESS
Sponsors Prevail Therapeutics

Most Recent Events

13 Nov 2020 According to a Prevail Therapeutics media release, initiation of patient enrollment remains on track for the fourth quarter of 2020 The optimized immunosuppression regimen used in the amended PROPEL trial will also be implemented in the PROCLAIM trial. The Company currently anticipates it will provide a biomarker and safety analysis on a subset of patients in the PROCLAIM trial in 2021.
26 Mar 2020 According to a Prevail Therapeutics media release, the company intends to initiate dosing in this trial in second half of 2020.
15 Jan 2020 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com